Canada's DRI Healthcare Q3 total income rises

DRI Healthcare Trust

05/11/2025 22:53

Overview

DRI Healthcare Q3 total income reaches $48.7 mln, comprehensive loss at $57.7 mln

Company repurchased 394,000 units for $4.1 mln under NCIB

DRI Healthcare acquired royalty interest in veligrotug and VRDN-003 for up to $300 mln

Outlook

Company increased credit facility by $70 mln to support acquisitions

Company plans to submit Biologics License Application for VRDN-003 by end of 2026

Result Drivers

INTERNALIZATION - DRI Healthcare completed internalization of investment management, paying a $48 mln termination fee to Persis Capital

ROYALTY ENTITLEMENT - DRI Healthcare increased its royalty entitlement on Ekterly sales through a one-time payment of $22 mln

VELIGROTUG & VRDN-003 ACQUISITION - Co acquired royalty interest in veligrotug and VRDN-003, expected to drive future growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Total Income
$48.75 mln
Q3 Adjusted Cash Earnings per Unit
$0.55
Q3 Net Income
-$57.86 mln
Q3 Adjusted EBITDA
$36.73 mln
Q3 Adjusted EBITDA Margin
84.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Dri Healthcare Trust is C$19.70, about 20.3% above its November 4 closing price of C$15.70

Press Release: ID:nCNWSjFlNa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)